Fig. 5.

Mutation detection rate from preoperative plasma and tumor tissue before and after the exclusion of CH‐related mutations. (A) Percentage of patients detected with at least one mutation from plasma. The mutation detection rate from plasma for stage I and stage II patients was reduced from 85% to 75% after the exclusion of CH‐related mutations that were detected from plasma. No differences were observed for stage III and IV patients. (B) Percentage of patients harbored at least one mutation from plasma or tumor tissue for longitudinal monitoring before and after the exclusion of CH‐related mutations.